2 hours ago
Description
(AWP Alliance News) - Shares of Moderna (MRNA) rose 11% after the biotech company showcased new research and early-stage development programs at its Science Day event, highlighting the expanding potential of its mRNA platform.
The stock is currently trading at $66.21, up $6.46 or 10.81%, on the Nasdaq. It opened at $59.82 after closing the previous session at $59.75. The stock has traded between $22.28 and $69.29 over the past 52 weeks.
Moderna outlined progress across multiple pipeline programs, including positive early validation of its mRNA-2808 T-cell engager for multiple myeloma, advancement of mRNA-2151 for ovarian cancer, and the introduction of its in vivo CAR-T program, mRNA-6007, for autoimmune diseases.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX